In all critical stages in the drug life cycle, BaiPharm can provide specific
recommendations and actionable solutions to clients.
WEBINARS
MORE >
Investigational New Drug (IND) Preparation for U.S. FDA Submission
[ Thursday, 26th September 2024 ]
Understanding Regulatory Requirements for Exporting Drugs to Cambodia, Laos, and Myanmar
[ Wednesday, 13th December 2023 ]
Understanding Regulatory Requirements for Exporting Drugs to Indonesia and Vietnam
[ Thursday, 30th November 2023 ]
LATEST NEWS
REGULATION
Monthly Recap: China Pharmaceutical Regulatory Updates | September 2024
Check out the latest pharma regulatory updates in China: 1. China CDE Solicits Public Comments on the 86th RLD Lists, 2.China Releases the Fifth List of Pediatric Drugs Encouraged for R&D, 3. China CDE Completes the Consultation on Q&A on Pharmaceutical Similarity Studies of Biosimilars; 4. China CDE Launches Patient-Centered Action for Rare Diseases Encouragement, 5. China NHSA Releases Expert Evaluation Results for Drugs Applied for Inclusion of 2024 NRDL
Oct 12, 2024
REGULATION
Monthly Recap: China Pharmaceutical Regulatory Updates | August 2024
Check out the latest pharma regulatory updates in China: 1. China CDE Solicits Public Comments on the 85th RLD Lists, 2. China NHSA Announces 440 Drugs Having Passed the Format Review for NRDL, 3. China NMPA Grants Five Rx-to-OTC Switches, 4. China Consults on the Overarching Regulation of Medical Devices, 5. China CDE Releases the 82nd RLD List...
Sep 12, 2024
REGULATION
China Releases The Fifth List of Pediatric Drugs Encouraged for R&D
On September 9, China's National Health Commission (NHC), Ministry of Industry and Information Technology (MIIT), National Healthcare Security Administration (NHSA), and National Medical Products Administration (NMPA) jointly announced the Fifth List of Pediatric Drugs Encouraged for R&D and Marketing Authorization, containing 15 drugs in total.
Sep 11, 2024